Package Leaflet: Information for the User
HBVAXPRO5micrograms, suspension for injection in pre-filled syringe
Hepatitis B vaccine (recombinant DNA)
Read all of this leaflet carefully before you or your child are vaccinated because it contains important information for you.
Contents of the package leaflet
This vaccine is indicated for active immunization against hepatitis B virus infection caused by all known subtypes, in individuals from birth to 15 years of age considered at risk of exposure to hepatitis B virus.
It can be expected that immunization with HBVAXPRO will also prevent hepatitis D, since hepatitis D does not occur in the absence of hepatitis B infection.
The vaccine does not prevent infections caused by other agents such as hepatitis A, hepatitis C, and hepatitis E, or by other pathogens known to infect the liver.
Do not use HBVAXPRO5micrograms
Warnings and precautions
May cause severe allergic reactions because it contains latex in the container.
Consult your doctor, pharmacist or nurse before you or your child receive HBVAXPRO 5 micrograms.
Other vaccines and HBVAXPRO5micrograms
HBVAXPRO can be administered at the same time as hepatitis B immunoglobulin, in different injection sites.
HBVAXPRO can be used to complete a primary immunization cycle or as a booster dose in individuals who have previously received another hepatitis B vaccine.
HBVAXPRO can be administered at the same time as some other vaccines, using different injection sites and syringes.
Tell your doctor, pharmacist or nurse if you or your child are taking or have recently taken any other medicines, including those obtained without a prescription.
Pregnancy and lactation
Caution should be exercised when prescribing the vaccine to pregnant or breastfeeding women.
Consult your doctor, pharmacist or nurse before using any medicine.
Driving and using machines
HBVAXPRO is expected to have no influence or negligible influence on the ability to drive and use machines.
HBVAXPRO5micrograms contains sodium:this medicine contains less than 23 mg of sodium (1 mmol) per dose; i.e., it is essentially "sodium-free".
Dose
The recommended dose per injection (0.5 ml) is 5 micrograms in individuals from birth to 15 years of age.
A vaccination cycle should include at least three injections.
Two vaccination schedules can be recommended:
In case of recent exposure to hepatitis B virus, a first dose of HBVAXPRO can be administered along with the appropriate dose of immunoglobulin.
Some local vaccination schedules currently recommend a booster dose. Your doctor, pharmacist or nurse will inform you if you need a booster dose.
Method of administration
The doctor or nurse will administer the vaccine by injection into the muscle. The preferred injection site in newborns and infants is the upper part of the thigh. The preferred injection site in older children and adolescents is the muscle of the upper arm.
This vaccine should never be administered into a blood vessel.
Exceptionally, the vaccine can be administered subcutaneously in patients with thrombocytopenia (decreased blood platelets) or in individuals at risk of bleeding.
If you or your child miss a dose of HBVAXPRO5micrograms
If you or your child miss a scheduled injection, consult your doctor, pharmacist or nurse. Your doctor or nurse will decide when to administer the missed dose.
If you or your child have any further questions about the use of this product, ask your doctor, pharmacist or nurse.
Like all medicines, this vaccine can cause side effects, although not everybody gets them.
As with other hepatitis B vaccines, in many cases, a causal relationship between side effects and the vaccine has not been established.
The most frequently observed side effects are injection site reactions: pain, redness, and induration.
Other side effects reported very rarely are:
In children born very prematurely (at 28 weeks of gestation or earlier), longer-than-normal intervals between breaths may occur during the 2 or 3 days following vaccination.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this vaccine out of the sight and reach of children.
Do not use this vaccine after the expiry date stated on the label.
Store in a refrigerator (between 2°C and 8°C).
Do not freeze.
Store in the original packaging to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of HBVAXPRO5micrograms
Hepatitis B surface antigen, recombinant (HBsAg)* ..... 5 micrograms Adsorbed on amorphous aluminum hydroxyphosphate sulfate (0.25 milligrams Al+)
The other ingredients are sodium chloride (NaCl), sodium borate, and water for injections.
Appearance and packaging ofHBVAXPRO5micrograms
HBVAXPRO 5 micrograms is a suspension for injection in a pre-filled syringe.
Pack sizes of 1, 10, 20, and 50 pre-filled syringes without a needle or with 2 separate needles.
Pack sizes of 1 and 10 pre-filled syringes with 1 separate needle.
Not all pack sizes may be marketed.
Marketing authorisation holder and manufacturer
Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, Netherlands
For further information about this vaccine, contact the local representative of the marketing authorisation holder.
België/Belgique/BelgienMSD BelgiumTél/Tel: +32(0)27766211dpoc_belux@msd.com | LietuvaUAB Merck Sharp & DohmeTel. +370 5 2780 247dpoc_lithuania@msd.com |
Luxembourg/LuxemburgMSD BelgiumTél/Tel: +32 (0) 27766211dpoc_belux@msd.com | |
Ceská republika Merck Sharp & Dohme s.r.o.Tel.: +420 233 010 111dpoc_czechslovak@merck.com | Magyarország MSD Pharma Hungary Kft.Tel.: + 36.1.888.5300hungary_msd@merck.com |
DanmarkMSD Danmark ApSTlf.: +45 4482 4000dkmail@msd.com | MaltaMerck Sharp & Dohme Cyprus Limited.Tel: 8007 4433 (+356 99917558)malta_info@merck.com |
DeutschlandMSD Sharp & Dohme GmbHTel.: +49 (0) 89 20 300 4500medinfo@msd.de | NederlandMerck Sharp & Dohme B.V.Tel: 0800 9999000 (+31 23 5153153)medicalinfo.nl@merck.com |
EestiMerck Sharp & Dohme OÜTel: +372 614 4200dpoc.estonia@msd.com | NorgeMSD (Norge) ASTlf: +47 32 20 73 00medinfo.norway@msd.com |
Ελλ?δαMSD Α.Φ.Ε.Ε.Τηλ: +30 210 98 97 300dpoc_greece@merck.com | ÖsterreichMerck Sharp & Dohme Ges.m.b.H.Tel: +43 (0) 1 26 044dpoc_austria@merck.com |
EspañaMerck Sharp & Dohme de España, S.A.Tel: +34 91 321 06 00msd_info@msd.com | PolskaMSD Polska Sp. z o.o.Tel.: +48 22 549 51 00msdpolska@merck.com |
FranceMSD FranceTél: +33 (0)1 80 46 40 40 | PortugalMerck Sharp & Dohme, LdaTel: +351 21 4465700inform_pt@merck.com |
HrvatskaMerck Sharp & Dohme d.o.o.Tel: +385 1 66 11 333croatia_info@merck.com | RomâniaMerck Sharp & Dohme Romania S.R.LTel: + 4021 529 29 00msdromania@merck.com |
IrelandMerck Sharp & Dohme Ireland (Human Health) LimitedTel: +353 (0)1 2998700medinfo_ireland@msd.com | SlovenijaMerck Sharp & Dohme, inovativna zdravila d.o.o.Tel: +386 1 520 4201msd.slovenia@merck.com |
ÍslandVistor ehf.Sími: + 354 535 7000 | Slovenská republikaMerck Sharp & Dohme, s. r. o.Tel: +421 2 58282010dpoc_czechslovak@merck.com |
ItaliaMSD Italia S.r.l.Tel: 800 23 99 89 (+39 06 361911)dpoc.italy@msd.com | Suomi/FinlandMSD Finland OyPuh/Tel: +358 (0)9 804 650info@msd.fi |
Κ?προςMerck Sharp & Dohme Cyprus LimitedΤηλ: 800 00 673 (+357 22866700)cyprus_info@merck.com | SverigeMerck Sharp & Dohme (Sweden) ABTel: +46 77 5700488medicinskinfo@msd.com |
LatvijaSIA Merck Sharp & Dohme LatvijaTel.: +371 67025300dpoc.latvia@msd.com |
Date of last revision of this leaflet:
Detailed information on this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu.
This information is intended only for healthcare professionals:
Instructions
A visual inspection of the vaccine should be performed to detect any possible appearance of foreign particles and/or abnormal physical appearance of the contents before administration. The syringe should be shaken well until a slightly opaque white suspension is obtained.
The needle is fixed by twisting it in the direction of the clock hands until it is securely attached to the syringe.